How can we successfully implement precision medicine strategies in diffuse large B-cell lymphoma (DLBCL)? In this review, we describe the recently proposed genomic categories of DLBCL and their potential use for personalized treatment.
No takes yet. Share an insight, caveat, or question.
Crombie et al. (2020) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: